Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
cross infection
MeSH D003428 - cross infection
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D007049:
Iatrogenic disease
0 Companies
0 Drugs
Success rate
D007239:
Infections
2 Companies
2 Drugs
$
Success rate
D003428:
Cross infection
2 Companies
2 Drugs
$
Success rate
D000077299:
Healthcare-associated pneumonia
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Johnson & Johnson
Doripenem
Doribax
2008-07-25
Clinical Trials
Historical Success Rate
Phase 1
100
%
3/3
Phase 2
36
%
5/14
Phase 3
58
%
11/19
Approved:
2
Overall Success rate:
21%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Johnson & Johnson
Doripenem
,
Clavulanate
,
Clavulin
,
Clavamox
,
Kcl
Theravance Biopharma
Telavancin
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use